Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03415685
Other study ID # L16004
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 12, 2017
Est. completion date October 3, 2018

Study information

Verified date November 2023
Source LUTRONIC Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the use of the Lutronic PicoPlus for treatment of dermatological conditions such as unwanted tattoos and benign pigmented lesions.


Description:

This pilot clinical trial will evaluate the capability of the Lutronic PicoPlus technology to remove unwanted tattoos and benign pigmented lesions. This trial is designed as a multi-center exploratory, open-label clinical trial comparing each subject's condition before and after treatment. Subjects meeting all entrance criteria will be assigned to Group A for treatment of unwanted tattoos and Group B for treatment of unwanted benign pigmented lesions, melasma, or other skin conditions such as skin rejuvenation. Subjects in each treatment group will receive a series of treatments, e.g., 2-5, and will be asked to complete 1 and 3 month follow-up visit(s) following each treatment to assess treatment efficacy and safety. At investigators' discretion, additional follow-up visits, e.g., at 6 months following treatment, may take place to observe the time course of reactions after treatment and/or assess efficacy. Outcome measures include clinician grading and subject satisfaction post-treatment. Pre-treatment study photos will be obtained at baseline; post-treatment study photos will be obtained at each post-treatment follow-up visit.


Recruitment information / eligibility

Status Terminated
Enrollment 39
Est. completion date October 3, 2018
Est. primary completion date September 6, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or Female - Adults between age 18 and 60 years old - Group A: Fitzpatrick skin type I - VI for unwanted tattoos and Group B: Fitzpatrick Skin Types I - IV for benign pigmented lesions and other conditions - Unwanted tattoo that contains single or multi-color ink, and - Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment - Ability to read, understand, and sign the Informed Consent Form - Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes. - Understands and accepts the obligation not to undergo any other procedures in the areas to be treated - Willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study Exclusion Criteria: - If receiving treatment for unwanted tattoo: double tattoos (tattoo over tattoo), history of allergic reactions to pigments following tattooing, local anesthetics or topical antibiotics - If receiving treatment for benign pigmented lesions including melasma: history of use of a lightening medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), or light-sensitive medication in the last 6 months - Known cardiovascular disease or cardiac surgery that in the opinion of the investigator would interfere with study treatments - Previous interventions or treatment with another device in the target area within 6 months of enrollment or during the study - Pregnant or lactating or planning pregnancy before end of study - Presence of an active systemic, local skin disease, medication or condition that may affect wound healing or interfere with participation or treatment to the active area. - Active or recurrent cancer of current chemotherapy or radiation therapy - History of seizure disorders due to light - History of vitiligo, eczema, or psoriasis - History of connective tissue disease, such as systemic lupus erythematosus or scleroderma - History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation - History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen - History of keloid scarring, hypertrophic scarring or of abnormal wound healing. - History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. - History of seizure disorders due to light. - Suffering from coagulation disorders or taking prescription anticoagulation medications - History of keloid scarring, hypertrophic scarring or of abnormal wound healing Any use of medication that is known to increase sensitivity to light according to Investigator's discretion - Excessive or recent significant tan in areas to be treated or unable/unlikely to refrain from tanning during the study - Current smoker or history of smoking within 3 months of study participation - Systemic use of corticosteroid or isotretinoin within 6 months of study participation - Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus - Any physical or mental condition including alcohol or drug abuse that in the opinion of the investigator could interfere with subject's suitability for inclusion in study

Study Design


Intervention

Device:
PicoPlus laser system
Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.

Locations

Country Name City State
United States Dermatology, Laser, and Vein Specialists of the Carolinas Charlotte North Carolina
United States Metro Dermatology Elmhurst New York
United States Laser and Skin Surgery Center of New York New York New York
United States Zena Medical Newport Beach California

Sponsors (1)

Lead Sponsor Collaborator
LUTRONIC Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Blinded Reviewer's Global Assessment of Improvement Three blinded experienced, non-treating clinicians will independently evaluate pre- and post-treatment photos of each subject, presented randomly. Each reviewer will be asked to determine the temporal order (before and after) of each photo pair, and then rate the degree of tattoo clearing or reduction in benign pigmentation in the post-treatment photo using the following scale:
3 = Very significant or complete clearing (75-100%)
2 = Significant clearing (50-74%)
1 = Moderate clearing (25-49%)
0 = Mild or no clearing (0-24%)
3-month (Group B), 6 months (Group A) Post Final treatment
Other Melasma Area Severity Index (MASI) Three blinded experienced, non-treating clinicians will independently evaluate pre- and post-treatment photos of each subject, presented randomly, using the MASI. Each of four regions (forehead, right malar region, left malar region and chin) will be assessed based on three variables: percentage of the total area involved (A), darkness (D), and homogeneity (H). 3 Months (Group B), 6 Months (Group A) post final treatment
Primary Investigator's Global Assessment of Improvement Overall aesthetic improvement based on completion of the Physician's Global Assessment of Improvement Scale. Physician evaluators will review study photos post-final treatment, and rate the degree of tattoo clearing or reduction in benign pigmentation observed in the subject's treated area using the following definitions:
3 = Very significant or complete clearing (75-100%)
2 = Significant clearing (50-74%)
1 = Moderate clearing (25-49%)
0 = Mild or no clearing (0-24%)
Up to 6 Months following final study treatment
Secondary Subject's Global Assessment of Improvement Overall aesthetic improvement based on completion of the Subject's Global Assessment of Improvement Scale. Subjects will be asked review study photos post-final treatment, and rate the degree of tattoo clearing or reduction in benign pigmentation observed in the subject's treated area using the following definitions:
3 = Very significant or complete clearing (75-100%)
2 = Significant clearing (50-74%)
1 = Moderate clearing (25-49%)
0 = Mild or no clearing (0-24%)
1 month, 3 Months, 6 Months (Group A Only) post final treatment
Secondary Subject Satisfaction Following the final study treatment, subjects will be asked to rate their level of satisfaction with the laser treatment outcome and the overall laser treatment procedure, using the Subject Satisfaction Assessment Scale and the following definitions:
2 = Extremely Satisfied
1 = Satisfied
0 = Neutral
(-1) = Unsatisfied
(-2) = Extremely Unsatisfied
1 month, 3 Months, 6 Months (Group A Only) post final treatment
See also
  Status Clinical Trial Phase
Completed NCT05013801 - A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma N/A
Recruiting NCT06174545 - Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma N/A
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Recruiting NCT06278948 - Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma N/A
Not yet recruiting NCT05911698 - Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. N/A
Recruiting NCT05656833 - Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma N/A
Recruiting NCT04597203 - Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial N/A
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Recruiting NCT04765930 - Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma N/A
Completed NCT04137263 - Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging N/A
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT05969587 - Cysteamine Compared to Hydroquinone in Melasma Phase 3
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Completed NCT05887219 - Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma Phase 1
Completed NCT05884151 - Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma Phase 1
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3
Not yet recruiting NCT05099601 - Silymarin Cream Versus Combined Silymarin Cream and Microneedling in Treatment of Melasma Phase 4